Tamoxifen resistance is a major problem in the treatment of estrogen receptor (ER)-positive patients. We have previously reported that hexamethylene bis-acetamideinducible protein 1 (HEXIM1) inhibits ERa activity by competing with ERa for binding to cyclin T1, a subunit of positive transcription elongation b (P-TEFb). This results in the inhibition of the phosphorylation of RNA polymerase II (RNAPII) at serine 2 and the inhibition of transcription elongation of ERa target genes. As HEX-IM1 can inhibit ER activity, we examined whether it has a critical role in the inhibitory effects of tamoxifen on ER. We observed that tamoxifen-induced HEXIM1 recruitment to the promoter region of ER target genes and decreased the recruitment of cyclin T1 and serine 2 phosphorylated RNAPII to the coding regions of these genes. Conversely, in cells wherein HEXIM1 expression has been downregulated we observed attenuation of the inhibitory effects of tamoxifen on estrogen-induced cyclin T1 recruitment to coding regions of ER target genes. As a consequence, downregulation of HEXIM1 resulted in the attenuation of the repressive effects of tamoxifen on estrogen-induced gene expression and proliferation. Conferring clinical relevance to our studies is our analysis of human breast cancer tissue samples that indicated association of lower expression of HEXIM1 with tumor recurrence in patients who received tamoxifen. Our studies provide a better understanding of the mechanistic basis for the inhibitory effect of tamoxifen on ER activity and may suggest new therapeutic targets for the treatment of tamoxifen-resistant breast cancer.
Tamoxifen resistance is a major problem in the treatment of estrogen receptor (ER)-positive patients. We have previously reported that hexamethylene bis-acetamideinducible protein 1 (HEXIM1) inhibits ERa activity by competing with ERa for binding to cyclin T1, a subunit of positive transcription elongation b (P-TEFb). This results in the inhibition of the phosphorylation of RNA polymerase II (RNAPII) at serine 2 and the inhibition of transcription elongation of ERa target genes. As HEX-IM1 can inhibit ER activity, we examined whether it has a critical role in the inhibitory effects of tamoxifen on ER. We observed that tamoxifen-induced HEXIM1 recruitment to the promoter region of ER target genes and decreased the recruitment of cyclin T1 and serine 2 phosphorylated RNAPII to the coding regions of these genes. Conversely, in cells wherein HEXIM1 expression has been downregulated we observed attenuation of the inhibitory effects of tamoxifen on estrogen-induced cyclin T1 recruitment to coding regions of ER target genes. As a consequence, downregulation of HEXIM1 resulted in the attenuation of the repressive effects of tamoxifen on estrogen-induced gene expression and proliferation. Conferring clinical relevance to our studies is our analysis of human breast cancer tissue samples that indicated association of lower expression of HEXIM1 with tumor recurrence in patients who received tamoxifen. OurIntroduction Lifetime exposure to estrogen is a major risk factor for breast cancer since estrogen has an important role in the initiation of tumorigenesis (Yager and Davidson, 2006) . Estrogen carries out its functions by activating nuclear receptors, estrogen receptor a (ERa) and estrogen receptor b (ERb) that function as ligand-dependent nuclear transcription factors (Mangelsdorf et al., 1995; Yager and Davidson, 2006) . When estrogen binds to ERa, the receptor changes conformation and binds to estrogen-responsive elements located in the promoter region of ERa target genes (Mangelsdorf et al., 1995; Gruber et al., 2002) . The interaction between ERa and estrogen-responsive element leads to the recruitment of other transcription factors that facilitate gene transcription (Mangelsdorf et al., 1995) . ERa target gene transcription mediates mammary cell proliferation, increased cell division and DNA synthesis that elevates the risk of replication errors and can initiate tumorigenesis (Deroo and Korach, 2006) .
Our laboratory identified an ER co-regulator, estrogen downregulated gene 1 as a protein whose expression is downregulated by estrogens (Wittmann et al., 2003) . Estrogen downregulated gene 1 is also known as hexamethylene-bis-acetamide (HMBA)-inducible protein 1 (HEXIM1) because it can be upregulated in vascular smooth muscle cells by the differentiating agent HMBA (Kusuhara et al., 1999) . HEXIM1 was shown to inhibit the positive transcription elongation factor b (P-TEFb) by interacting with the cyclin T1 subunit (Yik et al., 2003; Wittmann et al., 2005) . We have reported that cyclin T1 and 17-beta estradiol (E 2 )-liganded-ER interact on the promoter region of ER target genes allowing for ERa to compete with HEXIM1 for cyclin T1 (Wittmann et al., 2005; Ogba et al., 2008) . E 2 -liganded ER then enhances P-TEFb kinase activity and phosphorylation of RNA polymerase II (RNAP II) at serine 2, resulting in transcriptional elongation. On the contrary, increased HEXIM1 expression results in inhibition of cyclin T1 recruitment (Ogba et al., 2008) and inhibition of E 2 -induced phosphorylation of RNAP II at serine 2 (Ogba et al., 2008) . As a result, HEXIM1 inhibited estrogen-induced gene expression and proliferation (Ogba et al., 2008) . Furthermore, levels of HEXIM1 expression were decreased in breast tumor tissue when compared with adjacent normal breast tissues in all tumor grades (Wittmann et al., 2003) .
Approximately two-thirds of breast tumors express ERa (Cleator et al., 2009) . ERa is a valuable predictive factor since ERa-positive breast cancer cells depend on estrogen and can be treated with anti-estrogens such as tamoxifen (Lewis and Jordan, 2005) . Although, tamoxifen has different agonist or antagonist effects in different tissues, tamoxifen works as an antagonist in breast tissues by binding to ERa and blocking the interaction between estrogen and the ER (Musgrove and Sutherland, 1994) . It has been effectively used as an adjuvant therapy for ERa-positive patients to reduce mortality and prolong survival time (Osborne, 1998) . However, the efficacy of tamoxifen treatment is limited by the development of resistance, with approximately half of the patients developing tamoxifen resistance after 5 years of therapy (Anderson et al., 2007; Zwart et al., 2009) . Proposed bases for tamoxifen resistance include loss of ER expression/function, activation of growth factor signaling pathways that circumvent tumor reliance on ERa signaling, and alterations in the expression of co-regulatory proteins involved in mediating ER target gene transcription (Lavinsky et al., 1998; Ring and Dowsett, 2004; Riggins et al., 2007; Scott et al., 2007; Hurvitz and Pietras, 2008; Lahusen et al., 2009) .
More than 70% of tamoxifen-resistant tumors still express functional ER (Cleator et al., 2009 ) and because HEXIM1 inhibits ERa transcriptional activity, we hypothesized that HEXIM1 is a critical factor in the inhibition of ER activity by tamoxifen and loss of HEXIM1 may contribute to tamoxifen resistance. To investigate the hypothesis, we examined the recruitment of HEXIM1, cyclin T1 and serine 2 phosphorylated RNAP II to ER target genes in the presence of tamoxifen. Furthermore, we downregulated HEXIM1 expression to demonstrate a functional role for HEX-IM1 in the inhibition of ER activity by tamoxifen. To confer clinical relevance to our in vitro studies, immunohistochemical studies were conducted to examine if there was a correlation between HEXIM1 expression and disease recurrence in patients who had been treated with tamoxifen.
Results
Tamoxifen enhances the recruitment of HEXIM1 to ERa target genes We have previously reported that endogenous HEXIM1 interacted with E 2 -liganded ERa in breast cells and was recruited to the promoter regions of ERa target genes (Wittmann et al., 2005) . Moreover, we observed that trans-hydroxy-tamoxifen (TOT)-liganded ERa also interacted with HEXIM1 (Wittmann et al., 2005) . We hypothesized that HEXIM1 DNA binding was regulated by TOT. To investigate this hypothesis, we carried out chromatin immunoprecipitation assays in MCF-7 cells and examined the effect of TOT on HEXIM1 occupancy on the ER-target genes, pS2 and cyclin D1 (CCND1). In TOT-treated cells, we observed a significant increase in HEXIM1 occupancy at estrogen-responsive regions within the pS2 promoter when compared with vehicle or E 2 -treated cells (Figure 1a ).
We also observed increased HEXIM1 occupancy within the CCND1 promoter in TOT-treated cells (Supplementary Figure 1A ).
Tamoxifen inhibits the recruitment of cyclin T1 and phosphorylated RNAP II to ERa target genes Our previous studies indicated that HEXIM1 interacted with and inhibited ERa activity by competing with ERa for binding to the cyclin T1 subunit of P-TEFb. In doing Panel on the left, DNA fragments were analyzed by PCR using primers specific for the coding region of pS2. Panel on the right, quantifications of cyclin T1 enrichment at the pS2 promoter or coding regions. Each column represent the mean of three replicates; bars, s.e. *Po0.05. (c) Samples were processed for ChIP assays using antibodies against serine 2 phosphorylated RNAP II. Panel on the left, DNA fragments were analyzed by PCR using primers specific for coding region of pS2. Panel on the right, quantifications of RNAP II enrichment at the pS2 coding region. Columns represent the mean of three replicates; bars, s.e. *Po0.05.
HEXIM1 is critical for tamoxifen inhibition of the ER W Ketchart et al so, HEXIM1 inhibited phosphorylation of RNAP II carboxy-repeat terminal domain at serine 2 and transcriptional elongation by RNAP II (Yik et al., 2003; Wittmann et al., 2005; Ogba et al., 2008) . We determined whether TOT, by increasing HEXIM1 recruitment could also inhibit P-TEFb recruitment and the resulting phosphorylation of RNAP II. Chromatin immunoprecipitation assays were performed to study the binding of cyclin T1 and RNAP II to the promoter and coding regions of the pS2 gene. We examined both regions of ER target genes to investigate whether the effects of tamoxifen on the recruitment of cyclin T1 or phosphorylated RNAP II reflected effects on transcription initiation or elongation. We observed no significant decrease in cyclin T1 binding to the promoter region of pS2 as a result of TOT treatment ( Figure 1b ). As we previously reported, E 2 -induced recruitment of cyclin T1 to the coding region of the pS2 gene (Ogba et al., 2008) . However, TOT treatment resulted in attenuation of E 2 -induced cyclin T1 recruitment to the coding region of the pS2 and CCND1 genes ( Figure 1b and Supplementary Figure 1B) . We also examined recruitment of serine 2 phosphorylated RNAP II to the coding region of pS2 gene. Treatment with E 2 alone resulted in increased serine 2 phosphorylated RNAP II recruitment, but co-treatment with tamoxifen significantly decreased E 2 -induced serine 2 phosphorylated RNAP II recruitment to basal levels (P-value o0.05) (Figure 1c ). E 2 -induced recruitment of serine 2 phosphorylated RNAP II to the coding region of CCND1 was also significantly decreased in the presence of TOT (Supplementary Figure 1C) .
In summary, tamoxifen increased the recruitment of HEXIM1 to the promoter region of pS2 and CCND1 and attenuated E 2 -induced cyclin T1 and phosphorylated RNAP II recruitment to the coding region of both pS2 and CCND1, supporting a critical role of HEXIM1 in tamoxifen inhibition of ERa-mediated transcription.
Our previous studies indicated that E 2 increased PTEFb kinase activity. We also observed that HEXIM1 attenuated E 2 -induced P-TEFb activity (Ogba et al., 2008) . We hypothesized that tamoxifen would inhibit E 2 -induced P-TEFb activity. To investigate this, we measured the kinase activity of P-TEFb in endogenous immunoprecipitates of cyclin T1 from MCF-7 cells by examining phosphorylation of a synthetic peptide substrate (carboxy-repeat terminal domain-4). We observed that tamoxifen decreased E 2 -induced P-TEFb activity in MCF-7 cells (Supplementary Figure 2) , supporting inhibition of the transcription elongation process by tamoxifen.
Downregulation of HEXIM1 attenuates the repressive effects of tamoxifen on ERa-mediated transcriptional activity We further tested the critical role of HEXIM1 in tamoxifen inhibition of ERa-mediated transcription by downregulating HEXIM1 expression and examining repressive effects of tamoxifen on ERa-transcriptional activity. We developed MCF-7 cells stably transfected with expression vectors for control or HEXIM1 micro-RNA (miRNA) and confirmed that HEXIM1 protein expression was downregulated in HEXIM1 miRNAtransfected cells when compared with control miRNAtransfected cells (Figure 2a) . We did not observe any effects on ERa protein levels, indicating that effects of downregulating HEXIM1 levels cannot be attributed to changes in ERa levels (Supplementary Figure 3A) .
The recruitment of HEXIM1 to the promoter regions of pS2 and CCND1 genes was decreased in HEXIM1 miRNA-transfected cells when compared with control cells regardless of treatment (Figure 2b and Supplementary Figure 3B ). Recruitment of HEXIM1 in HEXIM1 miRNA-transfected cells was influenced by hormonal treatment, compounding the relationship between HEX-IM1 expression and promoter occupancy. Downregulation of HEXIM1 expression resulted in attenuation of the repressive effects of TOT on E 2 -induced cyclin T1 recruitment to the pS2 and CCND1 coding regions (Figure 2c and Supplementary Figure 3C ). Co-treatment with TOT induced an increase (although not statistically significant) in estrogen-induced recruitment of cyclin T1 to the pS2 coding region in HEXIM1 miRNA-transfected cells, rather than the decrease observed in controltransfected cells. Downregulation of HEXIM1 expression also resulted in increased basal and TOT-induced recruitment of serine 2 phosphorylated RNAP II to the pS2 coding region (Figure 2d ). These data further confirm that HEXIM1 is critical for the repressive effects of tamoxifen on E 2 -mediated transcription.
Downregulation of HEXIM1 results in attenuation of the inhibitory effects of tamoxifen on estrogen-induced gene expression and cell proliferation CCND1, an estrogen target gene, is a D-type cyclin that regulates G 1 -S cell cycle progression during cell proliferation. Our previous study reported that HEXIM1 downregulated CCND1 expression levels in breast epithelial cells in vitro and in mouse mammary glands (Ogba et al., 2008) . We hypothesized that downregulation of HEXIM1 would result in attenuation of inhibitory effects of tamoxifen on E 2 -induced gene expression and proliferation. To investigate this, control miRNA-and HEXIM1 miRNA-transfected MCF-7 cells were treated with E 2 or both E 2 and TOT for 3 h. In control cells, we observed that E 2 treatment increased CCND1 expression while TOT treatment attenuated E 2 -induced CCND1 expression (Figure 3a) . However, in HEXIM1 miRNA-transfected cells, we did not observe a significant decrease in E 2 -induced CCND1 expression as a result of TOT treatment (Figure 3a) . pS2 mRNA levels were significantly increased in TOT-treated HEXIM1 miRNA-transfected MCF-7 cells when compared with TOT-treated control-transfected cells (Supplementary Figure 4A) . We observed attenuation of TOT repressive affect as a result of downregulation of HEXIM1 expression in another breast epithelial cell line, T47D (Supplementary Figure 4B) .
As TOT had reduced capacity for inhibiting E 2 -ERregulated transcription as a result of downregulation of HEXIM1 is critical for tamoxifen inhibition of the ER W Ketchart et al HEXIM1 expression, we examined if downregulation of HEXIM1 expression will also attenuate the inhibition of breast cancer cell proliferation by tamoxifen. In control cells, tamoxifen significantly reduced E 2 -induced cell proliferation from 4-to 1.7-fold (Figure 3b ). On the contrary, inhibitory effects of tamoxifen were significantly attenuated in HEXIM1 miRNA-transfected cells. We also observed enhanced E 2 -induced proliferation in HEXIM1 miRNA-transfected cells (Figure 3b ).
HEXIM1 expression is associated with decreased probability of cancer recurrence in breast cancer patients who received tamoxifen treatment Our previous studies indicated reduced levels of HEXIM1 expression in breast cancer tissues when compared with normal adjacent breast tissue (Wittmann et al., 2003) . We also observed that breast tumor cells expressing HEXIM1 were more likely to express ERa than the proliferation marker Ki67. Since HEXIM1 has critical roles in the inhibitory effects of tamoxifen, we examined the expression levels of HEXIM1 in a casecontrol study of breast cancer patients treated with tamoxifen. This case-control study consisted of 58 matched pairs of ER-positive tumors specimens (116 patients), from patients matched with regard to four criteria; year of diagnosis, patient age at diagnosis, TNM stage (tumor size, lymph nodes, metastasis; I, II or III) and radiation therapy (yes or no). This group was limited to women with at least 5 years of follow-up. Cases were defined as having recurred earlier than their matched controls. HEXIM1 expression was assessed by immunohistochemical staining (Supplementary Figure 5) . The proportion of cases decreased with increased HEXIM1 expression (Figure 4) . The estimated odds ratio of HEXIM1 expression for the cases was o1, indicating that higher HEXIM1 expression was associated with lower probabilities of recurrence. The odds of recurrence (case versus control) decreased by an estimated factor of 0.84 for each 10% increase in HEXIM1 expression (Table 1) . These data support our in vitro studies revealing an important role for HEXIM1 in the inhibitory effects of tamoxifen and that loss of HEXIM1 may be a contributing factor to the development of tamoxifen resistance.
Discussion
This study provides novel evidence that HEXIM1 is critical for tamoxifen inhibition of ERa activity. Our studies also suggest that tamoxifen-liganded ER has activities on its own and a more proactive role beyond HEXIM1 is critical for tamoxifen inhibition of the ER W Ketchart et al competitively inhibiting the interaction of ERa with estrogens. Tamoxifen-liganded ERa-induced recruitment of HEXIM1 to ER target genes, resulting in the inhibition of recruitment of cyclin T1 and serine 2 phosphorylated RNAP II to the coding regions of these ER target genes. We also demonstrated a functional role for HEXIM1 in the inhibition of ER-mediated gene expression and proliferation by tamoxifen. Most importantly, our immunohistochemical studies indicate a correlation between HEXIM1 expression and disease recurrence in patients who have been treated with tamoxifen. Co-activator and co-repressor proteins have critical roles in mediating transcriptional activation by the ER, and enhancement of co-activator or inhibition of co-repressor expression may contribute to the tamoxifen-resistant phenotype (Ring and Dowsett., 2004; Scott et al., 2007) . Overexpression of the co-activators amplified in breast cancer 1 or nuclear co-activator-3 in breast cancer has been correlated with tamoxifen resistance and decreased overall survival (Lahusen et al., 2009) . Co-repressors have been reported to interact with tamoxifen-liganded ER (Lavinsky et al., 1998; Webb et al., 2003) . In vitro studies have indicated that reduced levels of co-repressors nuclear receptor corepressor (N-COR) and silencing mediator of retinoic and thyroid hormone receptor (SMRT) resulted in attenuation of the inhibitory effects of tamoxifen (Lavinsky et al., 1998) . However, modulation of the recruitment of amplified in breast cancer 1, nuclear coactivator-3, N-COR or SMRT to ER target genes by tamoxifen has not been reported. Correlations between the levels of known co-repressors and tamoxifen resistance in human breast tissue samples have also not been reported. We have previously reported that HEXIM1 interacts with tamoxifen-liganded ER (Wittmann et al., 2005) . We now report on the consequences of this interaction and show that tamoxifen enhances the recruitment of HEXIM1 to the promoters of ER target genes that, in turn, inhibits the recruitment of cyclin T1 and phosphorylated RNAP II.
To demonstrate the functional relevance of tamoxifen-induced recruitment of HEXIM1 in the inhibitory effects of tamoxifen, we stably downregulated HEXIM1 expression and showed that decreased HEXIM1 recruitment to the promoter region of pS2 and CCND1 resulted in attenuation of tamoxifen inhibition of E 2 -induced recruitment of cyclin T1. Moreover, downregulation of HEXIM1 resulted in the enhancement of E 2 -induced cell proliferation, and attenuated the inhibitory effects of tamoxifen on CCND1 expression and cell proliferation. Therefore, our studies provide Sections from tumor specimens obtained from matched 'control' and 'case' patients were stained for endogenous HEXIM1 as described in the 'Materials and methods' section. 'Cases' were defined as having recurred earlier than their matched controls. Shown is the graph of logit (log(p/(1-p)) proportion of patient (p) with breast cancer recurrence after tamoxifen within each of five approximately equal size groups based on HEXIM1 expression. (a) HEXIM1 miRNA-or control miRNA-transfected MCF-7 cells were treated with 10 nM E 2 ±100 nM TOT for 3 h. Proteins were extracted from cells and processed for western blot analyses as described in the 'Materials and methods section'. Levels of CCND1 protein were quantitated and normalized to GAPDH. Columns represent the mean of three independent replicates; bars, s.e. *Po0.05 vs E 2 -treated cells (b) HEXIM1 miRNA-or control miRNA-transfected MCF-7 cells were plated onto 96-well plates and treated with 10 nM E 2 , 100 nM TOT, or both 10 nM E 2 and 100 nM TOT for 7 days. MTT assays were performed as described in 'Materials and methods section'. Columns, mean of three independent replicates with five wells for each treatment group; bars, s.e. *Po0.05 vs E 2 -treated cells; **Po0.05 vs control-transfected cells with the same treatment.
evidence for a critical role of HEXIM1 in the inhibitory effects of tamoxifen. E 2 binds to ER at the hydrophobic pocket of ligand-binding domain that is sealed by helix 12 providing a platform for recruiting co-activator proteins. Tamoxifen also binds to ER at ligand-binding domain and repositions helix 12. A key difference between E 2 -liganded ER and selective estrogen receptor modulator-or tamoxifen-ER complex is that helix 12 is prevented from sealing the ligand-binding pocket (Shiau et al., 1998) . HEXIM1 has been shown to interact with the E/F domain of ERa in vitro (Wittmann et al., 2005) . The binding of tamoxifen to ER resulted in several residues exposing different side chains than those observed in E 2 -liganded ER (Shiau et al., 1998) , perhaps allowing for an interaction with HEXIM1 to be more energetically favored. On the basis of our current studies, we speculate that tamoxifen can enhance HEXIM1 recruitment to ER target genes because of conformational changes that occur after tamoxifen binds to ER that allows for higher affinity binding to HEXIM1 than E 2 -liganded ER. Further studies should be done to gain a better understanding of structural basis for the interaction of HEXIM1 with tamoxifen-liganded ER.
The clinical relevance of our findings was supported by our immunohistochemical analysis of HEXIM1 expression in human breast cancer specimens. Our studies indicated that lower expression of HEXIM1 was significantly associated with increased risk of tumor recurrence in patients who received tamoxifen treatment. Thus, we speculate that loss of HEXIM1 may be involved in the development of tamoxifen resistance. Therefore, therapies aimed at increasing HEXIM1 expression can be developed for tamoxifen-resistant patients to improve breast cancer survival. We are currently testing this possibility using mouse models generated in our laboratory.
